What is the role of MIV-711 in the treatment of osteoarthritis (OA)?

Updated: Oct 12, 2020
  • Author: Carlos J Lozada, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

MIV-711, a potent selective cathepsin K inhibitor, is potential disease-modifying agent. Athough MIV-711 was found to be no better than placebo in relieving pain in knee osteoarthritis, it has shown promise in reducing bone and cartilage damage. [110] In a phase 2a study in 244 patients with primary knee osteoarthritis, no statistically significant change in pain score occurred among patients randomly allocated to receive MIV-711 100 mg daily, MIV-711 200 mg daily, or placebo for 26 weeks. However, patients in the treatment groups demonstrated reductions in biomarkers of bone resorbption (CTX-I) and cartilage loss (CTX-II). [110] Hence, additional research is needed regarding the overall and long-term effects and possible benefits of this therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!